The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for blockbuster treatments and impressive returns is clear, the linked risks are also considerable. Many of these ven